Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Peer review comments on drug trials submitted to medical journals differ depending on sponsorship, results and acceptance: a retrospective cohort study.

van Lent M, IntHout J, Out HJ.

BMJ Open. 2015 Sep 30;5(9):e007961. doi: 10.1136/bmjopen-2015-007961. Review.

2.

Differences between information in registries and articles did not influence publication acceptance.

van Lent M, IntHout J, Out HJ.

J Clin Epidemiol. 2015 Sep;68(9):1059-67. doi: 10.1016/j.jclinepi.2014.11.019. Epub 2014 Nov 29.

3.
4.

Role of editorial and peer review processes in publication bias: analysis of drug trials submitted to eight medical journals.

van Lent M, Overbeke J, Out HJ.

PLoS One. 2014 Aug 12;9(8):e104846. doi: 10.1371/journal.pone.0104846. eCollection 2014.

5.

Data from industry funded trials are reliable enough to be published.

Out HJ.

BMJ. 2014 Feb 5;348:g1298. doi: 10.1136/bmj.g1298. No abstract available.

PMID:
24500353
6.

Effect of funding source on publication bias is not so clear cut.

van Lent M, Out HJ.

BMJ. 2013 Dec 23;347:f7582. doi: 10.1136/bmj.f7582. No abstract available.

PMID:
24366203
7.

Recommendations for a uniform assessment of publication bias related to funding source.

van Lent M, Overbeke J, Out HJ.

BMC Med Res Methodol. 2013 Sep 30;13:120. doi: 10.1186/1471-2288-13-120.

8.

Tackling conflicts of interest. Industry tie may be benchmark of quality.

van Lent M, Out HJ.

BMJ. 2011 Sep 6;343:d5607. doi: 10.1136/bmj.d5607. No abstract available.

PMID:
21896592
9.

Optimizing the gonadotrophin dose regimen.

Out HJ, Thomas LE.

Int Surg. 2006 Sep-Oct;91(5 Suppl):S15-24.

PMID:
17436601
10.

Recombinant follicle-stimulating hormone: gold standard or not?

Out HJ.

Reprod Biomed Online. 2005 Nov;11(5):536-9.

PMID:
16409694
12.

The gonadotrophin-releasing hormone antagonist ganirelix--history and introductory data.

Out HJ, Mannaerts BM.

Hum Fertil (Camb). 2002 Feb;5(1):G5-10; discussion G10-2, G41-8. Review.

PMID:
11939160
13.

The cost-effectiveness of IVF in the UK: a comparison of three gonadotrophin treatments.

Sykes D, Out HJ, Palmer SJ, van Loon J.

Hum Reprod. 2001 Dec;16(12):2557-62.

PMID:
11726574
14.

A randomized, double-blind clinical trial using fixed daily doses of 100 or 200 IU of recombinant FSH in ICSI cycles.

Out HJ, David I, Ron-El R, Friedler S, Shalev E, Geslevich J, Dor J, Shulman A, Ben-Rafael Z, Fisch B, Dirnfeld M.

Hum Reprod. 2001 Jun;16(6):1104-9.

PMID:
11387277
15.

Meta analysis on rFSH versus uFSH.

Out HJ, Hoomans EH, de Laat WN.

Hum Reprod. 2001 Mar;16(3):593-5. No abstract available.

PMID:
11228235
16.

Increasing the daily dose of recombinant follicle stimulating hormone (Puregon) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation.

Out HJ, Braat DD, Lintsen BM, Gurgan T, Bukulmez O, Gökmen O, Keles G, Caballero P, González JM, Fábregues F, Balasch J, Roulier R.

Hum Reprod. 2000 Jan;15(1):29-35.

PMID:
10611184
17.

Anovulatory infertility and the role of recombinant follicle-stimulating hormone (Recagon).

Out HJ.

J Indian Med Assoc. 1999 Feb;97(2):37-40, 58. No abstract available.

PMID:
10549190
18.

What are the clinical benefits of recombinant gonadotrophins?: the development of recombinant FSH (Puregon((R))): a scientific business.

Out HJ, Bennink HJ, de Laat WN.

Hum Reprod. 1999 Sep;14(9):2189-90. Review. No abstract available.

PMID:
10469679
19.

New stimulation regimens with recombinant FSH (Puregon) in in-vitro fertilization.

Out HJ.

Eur J Obstet Gynecol Reprod Biol. 1999 Jul;85(1):21-2. Review. No abstract available.

PMID:
10428317
20.

A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulation.

Out HJ, Lindenberg S, Mikkelsen AL, Eldar-Geva T, Healy DL, Leader A, Rodriguez-Escudero FJ, Garcia-Velasco JA, Pellicer A.

Hum Reprod. 1999 Mar;14(3):622-7.

PMID:
10221686
22.

Clomiphene citrate or gonadotrophins for induction of ovulation?

Out HJ, Coelingh Bennink HJ.

Hum Reprod. 1998 Sep;13(9):2358-61. No abstract available.

PMID:
9806246
23.

The use of a 100 IU starting dose of recombinant follicle stimulating hormone (Puregon) in in-vitro fertilization.

Devroey P, Tournaye H, Van Steirteghem A, Hendrix P, Out HJ.

Hum Reprod. 1998 Mar;13(3):565-6. No abstract available.

PMID:
9572411
25.

Pharmacodynamics and pharmacokinetics after repeated subcutaneous administration of three gonadotrophin preparations.

Duijkers IJ, Klipping C, Mulders TM, Out HJ, Coelingh Bennink HJ, Vemer HM.

Hum Reprod. 1997 Nov;12(11):2379-84.

PMID:
9436668
26.

Cryopreservation: the practicalities of evaluation.

Jones HW Jr, Out HJ, Hoomans EH, Driessen SG, Coelingh Bennink HJ.

Hum Reprod. 1997 Jul;12(7):1522-4.

PMID:
9262289
27.
28.

"The coming of wonders".

Out HJ, Olijve W, Coelingh Bennink HJ.

Fertil Steril. 1997 Feb;67(2):411-3. No abstract available.

PMID:
9022626
30.

Recombinant follicle stimulating hormone (rFSH; Puregon) in assisted reproduction: more oocytes, more pregnancies. Results from five comparative studies.

Out HJ, Mannaerts BM, Driessen SG, Coelingh Bennink HJ.

Hum Reprod Update. 1996 Mar-Apr;2(2):162-71. Review.

PMID:
9079411
31.

Clinical profiling of recombinant follicle stimulating hormone (rFSH; Puregon): relationship between serum FSH and efficacy.

Mannaerts BM, Rombout F, Out HJ, Coelingh Bennink H.

Hum Reprod Update. 1996 Mar-Apr;2(2):153-61. Review.

PMID:
9079410
32.

A bioequivalence study of two urinary follicle stimulating hormone preparations: Follegon and Metrodin.

Out HJ, Schnabel PG, Rombout F, Geurts TB, Bosschaert MA, Coelingh Bennink HJ.

Hum Reprod. 1996 Jan;11(1):61-3.

PMID:
8671157
33.
35.

A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies.

Out HJ, Bruinse HW, Christiaens GC, van Vliet M, de Groot PG, Nieuwenhuis HK, Derksen RH.

Am J Obstet Gynecol. 1992 Jul;167(1):26-32.

PMID:
1442938
36.

Detection of the lupus anticoagulant in pregnancy.

Derksen RH, Out HJ, Blokzijl L, de Groot PG.

Clin Exp Rheumatol. 1992 May-Jun;10(3):323-4. No abstract available.

PMID:
1582083
38.

Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies.

Out HJ, Kooijman CD, Bruinse HW, Derksen RH.

Eur J Obstet Gynecol Reprod Biol. 1991 Oct 8;41(3):179-86.

PMID:
1936501
39.

Prevalence of antiphospholipid antibodies in patients with fetal loss.

Out HJ, Bruinse HW, Christiaens GC, van Vliet M, Meilof JF, de Groot PG, Smeenk RJ, Derksen RH.

Ann Rheum Dis. 1991 Aug;50(8):553-7.

40.

Anti-phospholipid antibodies and pregnancy loss.

Out HJ, Bruinse HW, Derksen RH.

Hum Reprod. 1991 Jul;6(6):889-97. Review.

PMID:
1757531
41.

Antibodies to platelets in patients with anti-phospholipid antibodies.

Out HJ, de Groot PG, van Vliet M, de Gast GC, Nieuwenhuis HK, Derksen RH.

Blood. 1991 Jun 15;77(12):2655-9.

PMID:
2043767
42.

Antiphospholipid antibodies: risk factors or only markers for thrombosis, fetal loss and thrombocytopenia?

Out HJ, Kater L, Derksen RH.

Neth J Med. 1990 Apr;36(3-4):177-81. No abstract available.

PMID:
2355994
43.

Fluctuations of anticardiolipin antibody levels in patients with systemic lupus erythematosus: a prospective study.

Out HJ, de Groot PG, Hasselaar P, dan Vliet M, Derksen RH.

Ann Rheum Dis. 1989 Dec;48(12):1023-8.

44.

Systemic lupus erythematosus and pregnancy.

Out HJ, Derksen RH, Christiaens GC.

Obstet Gynecol Surv. 1989 Aug;44(8):585-91. Review. No abstract available.

PMID:
2668813
45.

[Disseminated lupus erythematosus and pregnancy].

Derksen RH, Out HJ, Christiaens GC.

Ned Tijdschr Geneeskd. 1989 May 20;133(20):1025-9. Dutch. No abstract available.

PMID:
2739776

Supplemental Content

Support Center